phospho stat5  (Cell Signaling Technology Inc)

Journal: Cell Reports Medicine

Article Title: Dual PD-1/IL-2Rα targeting restores CD8 + T cell fitness via STAT5/CD47 axis in SMARCA4-deficient NSCLC

doi: 10.1016/j.xcrm.2026.102633

Figure Lengend Snippet: Attenuated IL-2/STAT5 signaling and an enhanced exhaustion phenotype in CD8 + T cells within SMARCA4-deficient tumors (A) Schematic of the workflow for transcriptomic profiling of CD8 + T cells. (B) Volcano plot displaying differentially expressed genes in CD8 + T cells from SMARCA4-KD versus WT tumors. (C–E) Pathway enrichment analyses of genes downregulated in CD8 + T cells from SMARCA4-KD tumors, including Gene Ontology (GO) terms, KEGG pathways, and Reactome pathways. (F) The gene set enrichment analysis (GSEA) plot. (G) Correlation matrix (pie chart) showing the association between IL-2 receptor subunits expression and key T cell exhaustion marker genes in tumor-infiltrating CD8 + T cells. (H) Radar plot comparing the normalized expression levels of genes encoding IL-2 receptor subunits and exhaustion markers in CD8 + T cells. (I) Quantification by flow cytometry of the expression frequencies of PD-1, TIGIT, and TIM-3 on tumor-infiltrating CD8 + T cells. (J and K) Representative multiplex immunofluorescence (mIF) images of SMARCA4-WT and -KD tumor sections stained for PanCK (cyan), CD8 (green), GZMB (white), PD-1 (red), TIGIT (orange), and TIM-3 (yellow). Scale bars, 20 μm. Data are represented as mean ± SD (error bars) from biological replicates. Statistical analyses, n.s., no significance. Statistical significance was determined by unpaired Student’s t test or one-way ANOVA where appropriate.

Article Snippet: Stat5 (D2O6Y) Rabbit mAb , Cell Signaling Technology , Cat#94205; RRID: AB_2737403.

Techniques: Expressing, Marker, Flow Cytometry, Multiplex Assay, Immunofluorescence, Staining

Journal: Cell Reports Medicine

Article Title: Dual PD-1/IL-2Rα targeting restores CD8 + T cell fitness via STAT5/CD47 axis in SMARCA4-deficient NSCLC

doi: 10.1016/j.xcrm.2026.102633

Figure Lengend Snippet: SMARCA4 loss in tumor cells attenuates CD8 + T cell function via NF-κB-mediated suppression of ICAM1 (A) Flow cytometry analysis of surface expression of the exhaustion markers PD-1, TIGIT, and TIM-3 on human CD8 + T cells following co-culture. (B and C) Representative flow cytometry plots showing the production of IFN-γ and TNF-α and the surface expression of IL-2Rα (CD25) by CD8 + T cells following co-culture. (D) Quantification of the frequencies of IFN-γ + , TNF-α + , and IL-2Rα + cells among co-cultured CD8 + T cells. (E) Integrated single-nucleus RNA sequencing (snRNA-seq) analysis comparing IL2-STAT5 signaling activity. y axis: IL2-STAT5 signaling score. (F and G) Incoming and outgoing signaling patterns between major cell types in the TME, as inferred from snRNA-seq. (H) Specific cell-cell communication network illustrating the ICAM signaling pathway from tumor cells to CD8 + T cells in patients with SMARCA4-WT NSCLC. (I) Correlation analysis between SMARCA4 and ICAM1 mRNA expression in TCGA cohorts. (J) Immunohistochemistry staining and quantification of ICAM1 protein expression in tumor tissues from SMARCA4-WT ( n = 10) and -deficient ( n = 10) NSCLC patients. (K) Schematic illustrating the proposed link between SMARCA4 deficiency and impaired NF-κB activation. (L) Immunoblot analysis of ICAM1 and p65 protein levels in SMARCA4-WT H2122 cells treated with the NF-κB inhibitor PTDC or vehicle control. (M) ChIP-qPCR analysis showing NF-κB (p65) binding to a specific site within the ICAM1 promoter in SMARCA4-WT H2122 cells ( n = 3). (N) Dual-luciferase reporter assay in SMARCA4-WT H2122 cells ( n = 3). Data are represented as mean ± SD (error bars) from biological replicates. Statistical analyses, n.s., no significance, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. Statistical significance was determined by unpaired Student’s t test or one-way ANOVA where appropriate.

Article Snippet: Stat5 (D2O6Y) Rabbit mAb , Cell Signaling Technology , Cat#94205; RRID: AB_2737403.

Techniques: Cell Function Assay, Flow Cytometry, Expressing, Co-Culture Assay, Cell Culture, RNA Sequencing, Activity Assay, Immunohistochemistry, Staining, Activation Assay, Western Blot, Control, ChIP-qPCR, Binding Assay, Luciferase, Reporter Assay

Journal: Cell Reports Medicine

Article Title: Dual PD-1/IL-2Rα targeting restores CD8 + T cell fitness via STAT5/CD47 axis in SMARCA4-deficient NSCLC

doi: 10.1016/j.xcrm.2026.102633

Figure Lengend Snippet: STAT5 activation mediates the therapeutic effect of the PD-1/IL-2 bsAb in SMARCA4-deficient NSCLC (A) Representative flow cytometry plots showing the expression of the exhaustion markers PD-1, TIGIT, and TIM-3 on activated human CD8 + T cells. (B) Quantification of the mean fluorescence intensity (MFI) of the exhaustion markers PD-1, TIGIT, and TIM-3 on CD8 + T cells from the experiment in (A) ( n = 3). (C) Representative flow cytometry plots showing the production of IFN-γ and TNF-α by CD8 + T cells under the conditions described in (A). (D) Quantification of the frequencies of IFN-γ + and TNF-α + cells among CD8 + T cells ( n = 3). (E) Schematic of the adoptive T cell transfer experiment ( n = 8/group). (F) Representative in vivo bioluminescence images of mice from the indicated groups at different time points. (G) Tumor growth curves, as measured by bioluminescence, for mice in each treatment group. (H) Kaplan-Meier survival curves of mice from the four treatment groups. (I) Quantification of the frequency of donor-derived CD45.2 + CD8 + T cells among total tumor-infiltrating lymphocytes. (J) Flow analysis of donor-derived CD45.2 + CD8 + T cells expressing PD-1, TIGIT, and TIM-3. (K–M) Frequency of IFN-γ + (K–L) and TNF-α + (M) cells among donor-derived CD45.2 + CD8 + T cells. Data are represented as mean ± SD (error bars) from biological replicates. Statistical analyses, n.s., no significance. Statistical significance was determined by unpaired Student’s t test or one-way ANOVA or two-way ANOVA where appropriate.

Article Snippet: Stat5 (D2O6Y) Rabbit mAb , Cell Signaling Technology , Cat#94205; RRID: AB_2737403.

Techniques: Activation Assay, Flow Cytometry, Expressing, Fluorescence, In Vivo, Derivative Assay

Journal: Cell Reports Medicine

Article Title: Dual PD-1/IL-2Rα targeting restores CD8 + T cell fitness via STAT5/CD47 axis in SMARCA4-deficient NSCLC

doi: 10.1016/j.xcrm.2026.102633

Figure Lengend Snippet: PD-1/IL-2 bsAb protects CD8 + T cells from macrophage phagocytosis via STAT5-mediated upregulation of CD47 (A) Schematic of the Cleavage Under Targets and Tagmentation (CUT&Tag) assays workflow. (B) Distribution of STAT5 binding signals relative to transcription start sites (TSS) in CD8 + T cells treated with or without the PD-1/IL-2 bsAb. (C) Genomic annotation of differentially enriched STAT5 binding peaks in the bsAb-treated group. (D) KEGG pathway enrichment analysis of genes associated with STAT5 binding peaks. (E and F) Strategy and Venn diagram for identifying potential STAT5 downstream genes. (G) ChIP-qPCR analysis of STAT5 binding to the promoter regions of selected candidate genes ( n = 3). (H) Genome browser tracks showing STAT5 binding signals at the CD47 locus in control and PD-1/IL-2 bsAb-treated CD8 + T cells. (I) Schematic of the macrophage phagocytosis assay. (J) Representative confocal microscopy images showing macrophages (red) engulfing CD8 + T cells (green). Scale bars, 20 μm. (K) Flow cytometry quantification of the percentage of macrophages that had phagocytosed CD8 + T cells under the indicated conditions ( n = 3). Data are represented as mean ± SD (error bars) from biological replicates. Statistical analyses, n.s., no significance. Statistical significance was determined by unpaired Student’s t test or one-way ANOVA where appropriate.

Article Snippet: Stat5 (D2O6Y) Rabbit mAb , Cell Signaling Technology , Cat#94205; RRID: AB_2737403.

Techniques: Binding Assay, ChIP-qPCR, Control, Phagocytosis Assay, Confocal Microscopy, Flow Cytometry

Journal: JCI Insight

Article Title: Activating mutations in ESR1 contribute to an immunosuppressive breast tumor microenvironment by dampening cytokine secretion

doi: 10.1172/jci.insight.199927

Figure Lengend Snippet: ( A ) Immunoblot for Stat5, Stat3, p-Stat5, and p-Stat3 with their respective loading control (Tubulin or β-actin) on endpoint mammary tumor lysates of MIC WT, MIC ESR1-Y541S homo , and MIC ESR1-D542G homo mice. ( B – E ) Quantification of immunoblot for Stat5, Stat3, p-Stat5, and p-Stat3 normalized to their loading control, respectively. ( F ) Fluorescent IHC for ERα, p-Stat5, p-Stat3, PanCK, and DAPI on endpoint mammary tumors of MIC WT, MIC ESR1-Y541S homo , and MIC ESR1-D542G homo mice. ( G – I ) Quantification of p-Stat5 + cells, ERα + p-Stat5 + PanCK + cells, and p-Stat3 + cells, respectively. ( J ) Stat5 enrichment on Il1b and Il17a promoter sites detected by ChIP-qPCR in endpoint mammary tumors of MIC WT, MIC ESR1-Y541S homo , and MIC ESR1-D542G homo mice. Scale bars: 100 μm. Mean ± SEM for data calculated using 1-way ANOVA with Tukey’s multiple-comparison test.

Article Snippet: The following antibodies were used for immunoblots: β-actin (Sigma, A5441, 1:2000), tubulin (Cell Signaling Technology (CST), 2148, 1:1000), Cyclin D1 (CST, 2922, 1:500), FOXA1 (Abcam, ab23738, 1:1000), Stat3 (CST, 9139, 1:1000), Stat5 (CST, 94205, 1:1000), p-Stat3 (CST, 9145, 1:1000), and p-Stat5 (CST, 4322, 1:500).

Techniques: Western Blot, Control, ChIP-qPCR, Comparison

Journal: JCI Insight

Article Title: Activating mutations in ESR1 contribute to an immunosuppressive breast tumor microenvironment by dampening cytokine secretion

doi: 10.1172/jci.insight.199927

Figure Lengend Snippet: ( A ) Immunoblot for Stat5, Stat3, p-Stat5, and p-Stat3 with their respective loading control (Tubulin or β-actin) on endpoint mammary tumor lysates of MIC WT, MIC ESR1-Y541S homo , and MIC ESR1-D542G homo mice. ( B – E ) Quantification of immunoblot for Stat5, Stat3, p-Stat5, and p-Stat3 normalized to their loading control, respectively. ( F ) Fluorescent IHC for ERα, p-Stat5, p-Stat3, PanCK, and DAPI on endpoint mammary tumors of MIC WT, MIC ESR1-Y541S homo , and MIC ESR1-D542G homo mice. ( G – I ) Quantification of p-Stat5 + cells, ERα + p-Stat5 + PanCK + cells, and p-Stat3 + cells, respectively. ( J ) Stat5 enrichment on Il1b and Il17a promoter sites detected by ChIP-qPCR in endpoint mammary tumors of MIC WT, MIC ESR1-Y541S homo , and MIC ESR1-D542G homo mice. Scale bars: 100 μm. Mean ± SEM for data calculated using 1-way ANOVA with Tukey’s multiple-comparison test.

Article Snippet: The following antibodies were used for immunoblots: β-actin (Sigma, A5441, 1:2000), tubulin (Cell Signaling Technology (CST), 2148, 1:1000), Cyclin D1 (CST, 2922, 1:500), FOXA1 (Abcam, ab23738, 1:1000), Stat3 (CST, 9139, 1:1000), Stat5 (CST, 94205, 1:1000), p-Stat3 (CST, 9145, 1:1000), and p-Stat5 (CST, 4322, 1:500).

Techniques: Western Blot, Control, ChIP-qPCR, Comparison

Journal: Bone & Joint Research

Article Title: CXCL5 suppresses osteoclastogenesis and protects against lipoteichoic acid-induced bone loss by modulating PLCγ2 and c-Fos signalling in gram-positive periprosthetic joint infection

doi: 10.1302/2046-3758.153.BJR-2025-0290.R1

Figure Lengend Snippet: Chemokine (C-X-C motif) ligand 5 (CXCL5) does not significantly alter mitogen-activated protein kinase (MAPK), nuclear factor-kappa B (NF-κB), signal transducer and activator of transcription (STAT), or focal adhesion kinase (FAK) signalling during receptor activator of nuclear factor kappa-B ligand (RANKL)-induced osteoclast differentiation. a) and b) To investigate whether CXCL5 modulates early intracellular signalling in osteoclastogenesis, RAW264.7 cells were stimulated with RANKL (50 ng/ml) to induce osteoclast differentiation, with or without co-treatment with recombinant CXCL5. Western blot analysis was conducted to examine the phosphorylation status of MAPK pathway components (p38, JNK, and ERK) at various timepoints. No significant changes in the p-p38/p38, p-JNK/JNK, or p-ERK/ERK ratios were observed following CXCL5 co-treatment. c) and d) Similarly, NF-κB signalling activity was assessed by analyzing phospho-p65 levels over time. CXCL5 had no significant effect on RANKL-induced p65 phosphorylation. e) to g) The effects of CXCL5 on other osteoclast-related signalling molecules, including STAT5, STAT6, and FAK, were also evaluated in both time- and dose-dependent settings. No significant changes were detected in STAT5/6 phosphorylation or FAK expression levels. Data are presented as mean (standard error of the mean (SEM)) and were analyzed using one-way analysis of variance followed by Tukey’s multiple comparison test.

Article Snippet: Western blotting was performed using primary antibodies against the following targets: nuclear factor of activated T-cells cytoplasmic 1 (NFATc1) (4389), phospho-phospholipase Cγ2 (PLCγ2) (Tyr1217, 3871T), PLCγ2 (3872T), phospho-PLCγ1 (Tyr783, 2821T), PLCγ1 (5690T), c-Fos (4384), calcineurin A (2614S), phospho-p38 mitogen-activated protein kinase (MAPK) (Thr180/Tyr182, 9211), p38 MAPK (8690), phospho-SAPK/JNK (Thr183/Tyr185, 4668), SAPK/JNK (9252), phospho-ERK1/2 (4370), ERK1/2 (9102), phospho-nuclear factor-kappa B (NF-κB) p65 (Ser536, 3033), NF-κB p65 (8242), phospho-signal transducer and activator of transcription 5 (STAT5) (Tyr694, 9359S), STAT5 (94205T), phospho-STAT6 (Tyr641, 56554S), STAT6 (5397S), phospho-FAK (Tyr397, 3283S), and FAK (3285T) (all from Cell Signaling Technology, USA); TRAP (ab191406) and CXCR2 (ab217314; Abcam); CTSK (sc-48353), tumour necrosis factor receptor-associated factor 6 (TRAF6; sc-8409), and β-actin (sc-47778; Santa Cruz Biotechnology, USA).

Techniques: Recombinant, Western Blot, Phospho-proteomics, Activity Assay, Expressing, Comparison